NewAmsterdam Pharma Co. NV (NAMS)
29.30
-1.08
(-3.55%)
USD |
NASDAQ |
Jun 10, 16:00
29.30
0.00 (0.00%)
After-Hours: 18:27
NewAmsterdam Pharma Enterprise Value : 2.906B for June 9, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 09, 2026 | 2.906B |
| June 08, 2026 | 2.973B |
| June 05, 2026 | 3.039B |
| June 04, 2026 | 3.173B |
| June 03, 2026 | 3.108B |
| June 02, 2026 | 3.061B |
| June 01, 2026 | 3.071B |
| May 29, 2026 | 3.291B |
| May 28, 2026 | 3.494B |
| May 27, 2026 | 3.637B |
| May 26, 2026 | 3.584B |
| May 22, 2026 | 3.506B |
| May 21, 2026 | 3.541B |
| May 20, 2026 | 3.542B |
| May 19, 2026 | 3.305B |
| May 18, 2026 | 3.354B |
| May 15, 2026 | 3.506B |
| May 14, 2026 | 3.674B |
| May 13, 2026 | 3.776B |
| May 12, 2026 | 3.909B |
| May 11, 2026 | 3.991B |
| May 08, 2026 | 3.890B |
| May 07, 2026 | 3.437B |
| May 06, 2026 | 2.985B |
| May 05, 2026 | 2.852B |
| Date | Value |
|---|---|
| May 04, 2026 | 2.853B |
| May 01, 2026 | 2.686B |
| April 30, 2026 | 2.701B |
| April 29, 2026 | 2.686B |
| April 28, 2026 | 2.720B |
| April 27, 2026 | 2.922B |
| April 24, 2026 | 2.837B |
| April 23, 2026 | 3.040B |
| April 22, 2026 | 3.096B |
| April 21, 2026 | 3.160B |
| April 20, 2026 | 3.316B |
| April 17, 2026 | 3.417B |
| April 16, 2026 | 3.244B |
| April 15, 2026 | 3.338B |
| April 14, 2026 | 3.380B |
| April 13, 2026 | 3.591B |
| April 10, 2026 | 3.417B |
| April 09, 2026 | 3.453B |
| April 08, 2026 | 3.330B |
| April 07, 2026 | 3.318B |
| April 06, 2026 | 3.342B |
| April 02, 2026 | 3.211B |
| April 01, 2026 | 3.190B |
| March 31, 2026 | 3.096B |
| March 30, 2026 | 2.735B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ProQR Therapeutics NV | 77.22M |
| Pharming Group NV | 828.37M |
| Damora Therapeutics, Inc. | 863.89M |
| Dyne Therapeutics, Inc. | 2.163B |
| ACADIA Pharmaceuticals, Inc. | 2.936B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -48.44M |
| Revenue (Quarterly) | 3.04M |
| Total Expenses (Quarterly) | 51.48M |
| EPS Diluted (Quarterly) | -0.398 |
| Gross Profit Margin (Quarterly) | 97.96% |
| Profit Margin (Quarterly) | -1.59K% |
| Earnings Yield | -6.16% |
| Normalized Earnings Yield | -5.529 |